Biocept, Inc.

NasdaqCM:BIOC Stock Report

Market Cap: US$2.7m

Biocept Future Growth

Future criteria checks 2/6

Biocept is forecast to grow earnings and revenue by 56.6% and 67.1% per annum respectively while EPS is expected to grow by 77.3% per annum.

Key information

56.6%

Earnings growth rate

77.3%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate67.1%
Future return on equityn/a
Analyst coverage

Low

Last updated21 Sep 2023

Recent future growth updates

Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?

Dec 22
Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?

Recent updates

Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth

Apr 17
Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth

Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Nov 23
Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings

Aug 19
Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings

Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being

Jul 03
Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being

Biocept and CLEARED4 ink collaboration agreement

Jun 09

Biocept enters COVID-19 testing partnership

Apr 28

Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain

Mar 13
Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain

We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn Rate

Jan 26
We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn Rate

Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?

Dec 22
Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?

Biocept's assays viable and sensitive for detecting tumor cells and biomarkers

Nov 20

Biocept +4% on COVID-19 testing update

Nov 12

Earnings and Revenue Growth Forecasts

NasdaqCM:BIOC - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202521-17N/AN/A1
12/31/20246-23N/AN/A1
12/31/20232-22N/AN/A1
6/30/20231-31-18-18N/A
3/31/20237-37-19-19N/A
12/31/202226-32-14-13N/A
9/30/202241-25-9-7N/A
6/30/202257-16-5-4N/A
3/31/202263-812N/A
12/31/202161-324N/A
9/30/2021662-11N/A
6/30/202155-2-7-5N/A
3/31/202144-7-15-14N/A
12/31/202027-18-21-20N/A
9/30/202011-25-25-24N/A
6/30/20206-26-24-23N/A
3/31/20206-28-24-23N/A
12/31/20196-25-24-23N/A
9/30/20195-26-23-23N/A
6/30/20194-27-23-23N/A
3/31/20193-25-22-22N/A
12/31/20183-25-23-22N/A
9/30/20183-25-23-23N/A
6/30/20184-24-23-22N/A
3/31/20184-24-23-21N/A
12/31/20175-22-21-20N/A
9/30/20175-20-19-18N/A
6/30/20175-19-17-16N/A
3/31/20175-18N/A-15N/A
12/31/20163-18N/A-16N/A
9/30/20162-19N/A-16N/A
6/30/20161-19N/A-16N/A
3/31/20161-18N/A-16N/A
12/31/20151-17N/A-15N/A
9/30/20150-16N/A-14N/A
6/30/20150-16N/A-14N/A
3/31/20150-15N/A-13N/A
12/31/20140-16N/A-15N/A
9/30/20140-14N/A-13N/A
6/30/20140-13N/A-11N/A
3/31/20140-12N/A-10N/A
12/31/20130-9N/A-6N/A
9/30/20130-10N/A-7N/A
6/30/20130-10N/A-7N/A
3/31/20130-11N/A-8N/A
12/31/20120-12N/A-9N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIOC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BIOC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BIOC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BIOC's revenue (67.1% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: BIOC's revenue (67.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BIOC's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/15 13:40
End of Day Share Price 2023/10/13 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biocept, Inc. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raghuram SelvarajuAegis Capital Corporation
Sally YanchusBrookline Capital Markets
Kumaraguru RajaBrookline Capital Markets